使用GLP-1药物的患者中棕色脂肪组织在PET扫描上模拟头颈癌
报告一例接受GLP-1受体激动剂治疗的患者,FDG摄取增高的棕色脂肪组织在PET/CT上模拟转移性头颈癌。61岁女性III级肥胖患者,使用司美格鲁肽减重后出现右侧颈部肿块,PET/CT显示右侧II区淋巴结及颈部、纵隔广泛棕色脂肪摄取,造成诊断困惑。仔细融合解剖与功能数据解读PET/CT对鉴别高代谢棕色脂肪与恶性病变至关重要。
要点
- 使用GLP-1受体激动剂的患者中,棕色脂肪组织FDG摄取增高可模拟头颈癌区域转移。
- PET/CT图像判读需融合解剖与功能数据以鉴别高代谢棕色脂肪与恶性病变。
- 认识GLP-1受体激动剂与棕色脂肪摄取的相互作用对避免误诊和过度治疗至关重要。
核心结论
- 使用GLP-1受体激动剂的患者中棕色脂肪组织FDG摄取增高可干扰头颈癌评估,认识此相互作用对避免误诊和过度治疗至关重要。
研究设计与样本
- 病例报告:一例61岁女性III级肥胖患者,使用司美格鲁肽减重后出现右侧颈部肿块。
主要发现
- PET/CT显示右侧II区淋巴结FDG摄取及颈部、纵隔广泛棕色脂肪摄取,模拟弥漫性区域转移。
- 仔细融合解剖与功能数据解读PET/CT对鉴别高代谢棕色脂肪与恶性病变至关重要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To report a case of a patient undergoing GLP-1 receptor agonist therapy in which increased FDG uptake in brown adipose tissue (BAT) mimicked metastatic head and neck cancer on PET/CT imaging. A 61-year-old female with Class III obesity presented with a right-sided neck mass after significant weight loss following the use of the GLP-1 receptor agonist, Semaglutide. PET/CT revealed FDG uptake in the right level II lymph node and extensive BAT uptake throughout the neck and mediastinum, complicating the diagnosis. Increased FDG uptake in the cervical and supraclavicular BAT regions led to diagnostic confusion, mimicking diffuse regional metastasis. Careful interpretation of PET/CT imaging, with fusion of anatomical and functional data, was essential to differentiate hypermetabolic BAT from malignant disease. Increased BAT FDG uptake, particularly in patients using GLP-1 receptor agonists, can complicate the evaluation of head and neck cancer. Awareness of this interaction is critical to avoid misdiagnosis and overtreatment. Laryngoscope, 135:741-743, 2025.
引用
- Harrison DB, Phillips AL, Tansey JB, et al. Brown Adipose Tissue Mimicking Head and Neck Cancer on PET Scan in a Patient on GLP-1 Drug. Laryngoscope. 2024. PMID: 39370986. doi:10.1002/lary.31815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。